ReleaseWire Connect

DelveInsight has announced the addition of the "Cushing's Syndrome (CS) Market Insights, Epidemiology and Market Forecast-2027" to their offering.

DelveInsight has announced the addition of the "Cystic Fibrosis (CF) Market Insights, Epidemiology and Market Forecast-2027" to their offering.

DelveInsight has announced the addition of the " Cytomegalovirus (CMV) Infections Market Insights, Epidemiology and Market Forecast – 2027" to their offering.

DelveInsight has announced the addition of the "PD-1 & PDL-1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018".The report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. It covers the marketed drug profiles, pipeline drug profiles including clinical and non-clinical stage products. The report also included global sales, analyst insights of the marketed drugs. The PD-1 & PDL-1 inhibitor market evolution and class share evaluation are also included. It also provides therapeutics assessment by therapy type, stage, administration route and molecule type. It further highlights the inactive pipeline products in this space.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Vitiligo from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.Vitiligo is a long-term skin condition characterized by patches of the skin losing their pigment. The patches of skin affected become white and usually have sharp margins. The hair from the skin may also become white. The inside of the mouth and nose may also be involved. Typically both sides of the body are affected. Often the patches begin on areas of skin that are exposed to the sun. It is more noticeable in people with dark skin. Vitiligo may result in psychological stress and those affected may be stigmatized.

DelveInsight has announced the addition of the  "Hot Flashes - Market Insights, Epidemiologyand Market Forecast-2027'" drug pipelines to their offering. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hot Flashes from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Neuroendocrine tumors (NETs) consists of complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor)". Neuroendocrine tumors are classified based on different criteria as- Anatomic site of origin, symptoms, malignancy, grade and stage. NETs is more predominant in males as compared to females.

Atopic Dermatitis(AD) as the chronic or recurrent inflammatory skin disease, which belongs to the group of allergic disorders that includes food allergy, allergic rhinitis, and asthma. It is a chronic inflammatory skin disease and the clinical picture is characterized by widespread skin lesions, which manifest as red, itchy, swollen, cracked, weeping lesions with crusting/scaling, intractable pruritus and enhanced susceptibility to bacterial and viral skininfections. Atopic Dermatitis is classified as: Mild, Moderate and . In patients with moderate-to-severe Atopic Dermatitis, Pruritus is the most common and persistent disease that is prevalent. It is classified as Controlled Atopic Dermatitis and Uncontrolled Atopic Dermatitis on the basis of the disease controlled by using therapies. Uncontrolled Atopic Dermatitis is defined as currently flaring Atopic Dermatitis, deteriorating/changeable Atopic Dermatitis that cannot be controlled by therapies.

Myasthenia Gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuromuscular junction (NMJ). These proteins include the nicotinic Acetyl Cholinesterase (AChR) or, less frequently, a muscle-specific tyrosine kinase (MuSK). Clinically, MG has 2 major subtypes, primary ocular and generalized. MG often progresses to the more severe and generalized form with weakness of the head, neck, trunk, limb and respiratory muscles. The condition is classified from ocular to incubation stage MG from class I-V as: Class I (ocular), class II, III, IV (including IIa, IIIa, IVa & IIb, IIIb, IVb) as mild, moderate and severe generalized and Class V as intubation stage. The symptoms include breathing difficulties, fatigue, problems chewing and swallowing (choking), facial muscle weakness or paralysis such as eyelid drooping, difficulty talking, difficulty climbing stairs, a drooping head etc. Myasthenia Gravis is considered to be more prevalent in women as compared to men.

Thrombocytopenia can be defined as the deficiency of platelets (thrombocytes) which increases the risk of bleeding. In this condition, the platelet count of a patients drops down to less than 150 x 103 per ?L. Typically, platelet counts higher than 50 x 109 per L do not lead to clinical problems unless platelet dysfunction co-exists with the low count; rather, they are picked up on a routine complete blood count. A normal platelet count in adults ranges from 150,000 to 450,000 platelets per microliter of blood. A platelet count of less than 150,000 platelets per microliter, indicates the condition of thrombocytopenia. Thrombocytopenia is more prevalent in women than men, with 2.6 cases among women for every case involving a male.